{"id":44686,"date":"2022-06-03T20:01:40","date_gmt":"2022-06-03T18:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/"},"modified":"2022-06-03T20:01:40","modified_gmt":"2022-06-03T18:01:40","slug":"octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/","title":{"rendered":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights"},"content":{"rendered":"
\n

\nCompany\u2019s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient\u2019s level of disease activity as well as overall disease activity of a clinic\u2019s population<\/i>\n<\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE)–Octave<\/a>, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the company\u2019s novel MS Disease Activity (MSDA) test. The data was shared in a poster presentation at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting.\n<\/p>\n

<\/a><\/p>\n

\nThe poster, titled Multivariate Proteomic MS Disease Activity Test Results Surfaces Both Individual Patient and Clinical Practice Population Insights <\/b>(Qureshi, F., et al.), highlighted the MSDA test\u2019s observed score distributions in a well-controlled population of patients with MS, and showed that in a population of 222 patients, results from the test could track an individual patient\u2019s level of disease activity (DA) as well as effectively monitor DA across the entire clinic\u2019s population.\n<\/p>\n

\nThe Octave MSDA test is a novel, clinically-validated biomarker blood test that measures patients\u2019 disease biology, revealing underlying activated pathways and mechanisms, including quantitative analysis of serum proteins, to create unique MS signatures. The test is one dimension of the Octave MS Precision Care Solution, in development to address the complex unmet needs of MS and other neurodegenerative diseases.\n<\/p>\n

\n\u201cThe MS community is striving to help facilitate objective, value-based care for a patient population that, to this point, has been difficult to manage and track \u2013 it is critical that we better characterize these patients\u2019 underlying biology and disease activity over time in clinical practice to optimize their treatment,\u201d said Mike Edgeworth, MD, Chief Population Health Officer of Octave. \u201cWe see the continued validation of Octave\u2019s MSDA test as encouraging steps as we build the model for the future of MS management and beyond, producing insights that will benefit not only individual patients, but whole practices and entire health systems as well.\u201d\n<\/p>\n

\nPrevious data from the company demonstrated that the MSDA test is strongly associated with radiographic and clinical disease activity endpoints. Multiple studies, including clinical validation results and independent cohort replication, have shown that the test can serve as a quantitative and objective tool to enhance the care of MS with the potential to positively impact these patients at a population level.\n<\/p>\n

\nData presented by Octave to date support the launch of the company\u2019s precision care solution as the company actively develops novel measurement tools that feed structured analytical data models to improve patient management decisions, create better outcomes, and lower costs, ultimately benefiting patients, their physicians, and the entire health care system.\n<\/p>\n

\nAbout Multiple Sclerosis<\/b>\n<\/p>\n

\nMS is a chronic, lifelong, debilitating disease that affects approximately three million patients globally (one million of whom are in the US), affecting people as early as in their 20\u2019s with a 3:1 prevalence in women. The disease is driven by autoimmune and inflammatory processes as well as neurodegeneration, including demyelination and axonal damage. Estimated lifetime cost of MS is more than $4.8 million per patient and the estimated annual direct medical cost in the US alone is $63 billion, with a total economic burden of $85 billion.1,2<\/sup> MS is ranked second, behind only congestive heart failure, in direct all-cause medical costs. While there are now more than 22 approved treatments called disease modifying treatments, drug prices have continued to rise, costing between $60,000 and $100,000 per year.2<\/sup>\n<\/p>\n

\nAbout Octave\u2019s Comprehensive Precision Care Solution<\/b>\n<\/p>\n

\nOctave\u2019s fully-integrated precision care solution provides a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. It provides multiple dimensions of insight to reveal a 360-degree view with a longitudinal perspective of a patient. The first dimension measures the patient\u2019s underlying biology with blood-based biomarkers that quantitatively and objectively assess inflammation, immune modulation, axonal damage, and demyelination. The second dimension includes advanced measurement using improved MRI readings and interpretation to reveal more insights at the CNS layer, including the brain and spine. The final dimension features real-time tracking of symptoms via mobile tools, sensors and wearables to identify changes in disease, and alert care teams. All of this data is integrated into protocols, supported by decision support tools and feeds into a dashboard for ease of use. The Octave Precision Care Solution allows individual and population level views to facilitate better stratification and contextual interventions.\n<\/p>\n

\nAbout Octave<\/b>\n<\/p>\n

\nOctave was founded to deliver a fully-integrated precision care solution for multiple sclerosis as well as a full range of neurodegenerative diseases. Its comprehensive insights provide neurologists and their patients with objective metrics to facilitate informed care and shared decision making for better patient outcomes. Octave is headquartered in Menlo Park, California.\n<\/p>\n

    \n
  1. \nOptum.com. \u201cSix Cost Drivers of Multiple Sclerosis.\u201d\n<\/li>\n
  2. \nWexler M. #ECTRIMS2021 \u2013 Economic Burden of MS in US Exceeded $85B in 2019. Multiple Sclerosis News Today.<\/i> October 18, 2021. https:\/\/multiplesclerosisnewstoday.com\/<\/a>. Accessed June 1, 2022.\n<\/li>\n
  3. \nJ.Med Econ.2013; 16(5):639-47\u00a0\n<\/li>\n<\/ol>\n

    Contacts<\/b> <\/p>\n

    \nMedia Contact:<\/b>
    Terri Clevenger
    \n
    Westwicke\/ICR Healthcare PR
    \n
    Tel: 203.856.4326<\/b>
    Terri.Clevenger@icrinc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Company\u2019s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient\u2019s level of disease activity as well as overall disease activity of a clinic\u2019s population MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44686","6":"format-standard","7":"category-industry"},"yoast_head":"\nOctave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company\u2019s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient\u2019s level of disease activity as well as overall disease activity of a clinic\u2019s population MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-03T18:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights\",\"datePublished\":\"2022-06-03T18:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/\"},\"wordCount\":849,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005436\\\/en\\\/1476166\\\/21\\\/Octace.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/\",\"name\":\"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005436\\\/en\\\/1476166\\\/21\\\/Octace.jpg\",\"datePublished\":\"2022-06-03T18:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005436\\\/en\\\/1476166\\\/21\\\/Octace.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005436\\\/en\\\/1476166\\\/21\\\/Octace.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/","og_locale":"en_US","og_type":"article","og_title":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend","og_description":"Company\u2019s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient\u2019s level of disease activity as well as overall disease activity of a clinic\u2019s population MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-03T18:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights","datePublished":"2022-06-03T18:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/"},"wordCount":849,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/","url":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/","name":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg","datePublished":"2022-06-03T18:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220603005436\/en\/1476166\/21\/Octace.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/octave-presents-data-at-the-cmsc-2022-annual-meeting-showing-its-multiple-sclerosis-disease-activity-biomarker-test-produces-clinical-practice-population-insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44686"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44686\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}